15 results about "Aquaporin" patented technology

This application relates to a pharmaceutical composition of an aquaporin inhibitor and a method for producing the same. The pharmaceutical composition comprises 2-((3,5-bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and meglumine. The pharmaceutical composition of an aquaporin inhibitor and a method for producing the same have the following advantages: the process is simple, easy to operate, conducive to industrial production, good product stability, and a significantly reduced content of degradable impurities, which ensures pharmaceutical efficacy.

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

The application belongs to the technical field of microorganisms, and discloses a propionic acid-producing propionic acid bacteria NHNK-621 and application of the propionic acid bacteria in preparation of products for improving constipation and memory, the bacteria strain has been preserved in the China Center for Type Culture Collection on November 25, 2024, and the number is CCTCC NO: M 20242631. The propionic acid bacteria NHNK-621 provided by the application has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, up-regulating intestinal defensin and mucin gene expression, in addition, the bacterial biofilm can increase the colonization ability to intestinal epithelial cells, and can be used for preparing products for improving constipation and memory.

The application discloses a two-compartment modeling and prediction method for sodium kinetics in hemodialysis. The method divides the patient's body fluid into two compartments of extracellular fluid and intracellular fluid, and establishes a coupled differential equation set to describe the sodium transfer kinetics in the dialysis process. The application corrects the physical error of the existing model in the dispersion equilibrium concentration formula, proposes C_eq=[Na]d / σ (σ=0.97 is the Gibbs-Donnan factor) to replace the traditional Donnan formula and the old recommended formula, eliminates the false dispersion gradient under the condition of isonatric dialysis based on the physical fact that electrolytes are only distributed in the plasma water phase, and removes the error solvent drag term by clearly defining the biophysical constraints of the cell membrane aquaporin not transporting sodium. The application adopts a perturbation reference model to replace the traditional Fick diffusion law to describe the cell membrane sodium exchange, and more accurately reflects the intracellular and extracellular sodium kinetics. The model can accurately predict the serum sodium change and sodium removal under different dialysis prescriptions, and can generate a sodium removal contour map for clinical prescription optimization.

The present invention relates to delivering benefits related to maintaining a resilient microbiome on skin through a personal care composition, especially through wash off compositions like soap, body wash or shampoo. This is achieved by using starch or its microbial metabolite preferably in such compositions. It works by upregulating expression levels of Aquaporin-3, Claudin 1, Keratin- 4, Filaggrin- 1 or Desmoglein 1 on skin.

The present disclosure relates to a cosmetic composition containing an extract of Cyperus rotundus extracted using warm microbubbles. The extract inhibits nitric oxide (NO) production and exhibits excellent anti-inflammatory efficacy by inhibiting the expression of interleukin 6 (IL-6), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), which are inflammatory expression factors. In addition, the extract enhances the expression of aquaporin-3 (AQP-3), hyaluronan synthase 2 (HAS-2), claudin-1 (CLDN-1), cadherin 1 (CDH1), filaggrin (FLG), and involucrin (IVL), which are genes related to the skin barrier and moisturizing. Thus, when using the extract for cosmetic products, excellent effects can be exhibited in skin soothing, moisturizing, enhancement of the skin barrier, relief of irritation such as erythema, relief of pruritus, and the like, so the extract can be usefully applied to multi-care products that improve skin conditions.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and temozolomide for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER270 and TMZ. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. The composition provided by the invention provides an effective drug combination strategy for treatment of brain glioma, and it is found for the first time that the combination of AER270 and TMZ has a synergistic effect on treatment of brain glioma.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and amphotericin B for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER-270 and amphotericin B. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. The tumor cell inhibition effect of the pharmaceutical composition provided by the invention is obviously better than that of single AER270 or amphotericin B, the pharmaceutical composition has an obvious synergistic effect, and an effective drug combination strategy is provided for treatment of brain glioma.

This invention provides a method based on upland cotton GhMP This research relates to the field of genetic engineering technology and describes a method for the coordinated regulation of cotton fiber elongation and Verticillium wilt resistance using genes, as well as transgenic cotton plants. The gene encodes a membrane protein, and experiments using overexpression and RNA interference transgenic lines have demonstrated its effectiveness. GhMP The expression level of this compound is positively correlated with fiber development and disease resistance: increased expression significantly increases fiber length and improves resistance to Verticillium wilt, while decreased expression leads to fiber shortening and weakened resistance. Further studies have shown that... GhMP Proteins are located on the cell membrane and can interact with... GhPIP2.7 and GhTIP1.1 Aquaporins interact and jointly participate in the transmembrane transport of hydrogen peroxide, forming a molecular complex that regulates fiber elongation and disease resistance. This invention provides a key target gene that combines quality improvement and disease resistance enhancement, offering a new strategy and gene resource for multi-trait molecular breeding of cotton, and has significant application value and promising prospects.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and an oxidative phosphorylation inhibitor for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER-270 and an oxidative phosphorylation inhibitor Gboxin. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. According to the composition provided by the invention, through combined administration of the AER270 and the Gboxin, the inhibition effect on the brain glioma is obviously better than that of single AER270 or single Gboxin, the combination of the AER270 and the Gboxin has a synergistic effect on treatment of the brain glioma, and an effective drug combination strategy is provided for treatment of the brain glioma.

This invention discloses a small basic membrane intrinsic protein TtSIP1;2 of mitochondrial aquaporin and its encoding gene. TtSIP1; 2 Its cDNA reading frame sequence is shown in SEQ ID NO.2, and the encoded amino acid sequence is shown in SEQ ID NO.1. This invention... TtSIP1;2 The gene-encoded protein TtSIP1;2 is associated with the tolerance of Saccharomyces cerevisiae to high salt, high osmotic pressure (simulated drought), high temperature, and H2O2 (oxidative stress). TtSIP1;2 The gene can enhance yeast's tolerance to various abiotic stresses, improve its survival rate under stress, and promote yeast vitality. Overexpression of this gene in Arabidopsis thaliana can improve the salt and drought tolerance of transgenic plants. This invention... TtSIP1;2 Genes can be applied to the genetic improvement of stress tolerance in engineered bacteria and plants, and can be used to cultivate transgenic engineered bacteria or plant varieties with improved tolerance to high salt, drought, high temperature and oxidative stress.

This invention provides a SNP site for Co(a-b-) blood type that triggers immune hemolytic transfusion reactions, a blood typing kit, a method for identification, and its application, relating to the field of biotechnology. The SNP site includes a c.168delC deletion mutation at position 168, starting from the start codon in the AQP1 gene coding region. This mutation is a pathogenic SNP site for Co(a-b-) blood type, and the alleles it forms prevent the normal expression of Aquaporin-1 protein on the erythrocyte membrane, resulting in the absence of Co... a Antigen, and no Co b The antigen was identified as the Co(a-b-) phenotype. This provides a genetic variation basis for the establishment of rare blood type banks and the assurance of transfusion compatibility, and can be used for Co(a-b-) blood type identification. The identification of the new allele also provides a new research target for exploring the association mechanism between Colton blood type and certain diseases, contributing to the optimization of personalized medicine strategies.

This invention relates to a method for functionalizing nanofiltration membranes based on in-situ polymerization of hydroxylamine and its application. To address the problems of low separation efficiency and mutual constraints between permeability and retention capacity in existing nanofiltration membranes, this invention selects hydroxylamine as the monomer for the adsorption layer, constructing an adsorption functional layer on the surface of a traditional polyamide nanofiltration membrane. In-situ polyesterification crosslinking during the traditional interfacial polymerization process effectively simplifies the material preparation process. Benefiting from the abundant hydroxyl groups on the hydroxylamine surface, the functional membrane exhibits high hydrophilicity and permeability. The secondary polymerization process optimizes the internal network structure of the polyesteramide, reduces the pore size, and improves the separation capacity of the nanofiltration membrane. Under the coupling effect of adsorption and separation, the functional membrane demonstrates good treatment effects for novel pollutants such as bisphenol A and levofloxacin. This invention belongs to the field of water treatment membrane material preparation technology.

The invention provides an application of a dandelion water extract in preparation of a composition for improving muscle mass and skin moisture content, the dandelion water extract is obtained by extracting dandelion with a solvent, and the solvent is water. The dandelion water extract is further used for reducing the expression quantity of PPARG2 gene, C / EBP-alpha gene and GLUT4 gene and increasing the expression quantity of UCP1 gene and CETP gene so as to achieve the effects of reducing fat accumulation, promoting cholesterol metabolism, increasing muscle mass and promoting aquaporin generation.